메뉴 건너뛰기




Volumn 13, Issue 9, 2011, Pages 667-675

Angiotensin-converting enzyme inhibitors

Author keywords

[No Author keywords available]

Indexed keywords

ACEON PLUS; AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN I; ANGIOTENSIN II; BENAZEPRIL; BRADYKININ; CAPTOPRIL; CAPTOPRIL PLUS HYDROCHLOROTHIAZIDE; CHLORTALIDONE; CILAZAPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE I; ENALAPRIL; ENALAPRIL MALEATE; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; FOSINOPRIL; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; HYDROCHLOROTHIAZIDE PLUS MOEXIPRIL; HYDROCHLOROTHIAZIDE PLUS QUINAPRIL; INHIBACE PLUS; KININASE; LISINOPRIL; MOEXIPRIL; PERINDOPRIL; QUINAPRIL; RAMIPRIL; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

EID: 80052548674     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2011.00508.x     Document Type: Review
Times cited : (91)

References (92)
  • 1
    • 0017578611 scopus 로고
    • Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents
    • Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science. 1977;196:441-444.
    • (1977) Science , vol.196 , pp. 441-444
    • Ondetti, M.A.1    Rubin, B.2    Cushman, D.W.3
  • 2
    • 0033966332 scopus 로고    scopus 로고
    • Implications of species difference for clinical investigation: studies on the renin-angiotensin system
    • Hollenberg NK. Implications of species difference for clinical investigation: studies on the renin-angiotensin system. Hypertension. 1999;35:150-154.
    • (1999) Hypertension , vol.35 , pp. 150-154
    • Hollenberg, N.K.1
  • 3
    • 0016235926 scopus 로고
    • Pharmacokinetic function of the pulmonary circulation
    • Bakhle YS, Vane JR. Pharmacokinetic function of the pulmonary circulation. Physiol Rev. 1974;54:1007-1045.
    • (1974) Physiol Rev , vol.54 , pp. 1007-1045
    • Bakhle, Y.S.1    Vane, J.R.2
  • 4
    • 0006862091 scopus 로고    scopus 로고
    • Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans
    • Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation. 1997;95:1115-1118.
    • (1997) Circulation , vol.95 , pp. 1115-1118
    • Hornig, B.1    Kohler, C.2    Drexler, H.3
  • 5
    • 0009013562 scopus 로고
    • Renin and angiotensin tachyphylaxis
    • Bock KD, Gross F. Renin and angiotensin tachyphylaxis. Circ Res. 1961;9:1044-1050.
    • (1961) Circ Res , vol.9 , pp. 1044-1050
    • Bock, K.D.1    Gross, F.2
  • 6
    • 0023649967 scopus 로고
    • Angiotensin I-converting enzyme in isolated human glomeruli
    • Chansel D, Morin JP, Borghi H, et al. Angiotensin I-converting enzyme in isolated human glomeruli. FEBS Lett. 1987;220:247-252.
    • (1987) FEBS Lett , vol.220 , pp. 247-252
    • Chansel, D.1    Morin, J.P.2    Borghi, H.3
  • 7
    • 0017250864 scopus 로고
    • The role of the renin-angiotensin-aldosterone system in cardiovascular homeostasis in normal human subjects
    • Sancho J, Re R, Burton J, et al. The role of the renin-angiotensin-aldosterone system in cardiovascular homeostasis in normal human subjects. Circulation. 1976;53:400-405.
    • (1976) Circulation , vol.53 , pp. 400-405
    • Sancho, J.1    Re, R.2    Burton, J.3
  • 8
    • 0022485669 scopus 로고
    • Time course of changes in blood pressure, aldosterone and body fluids during enalapril treatment: a double-blind randomized study vs hydrochlorothiazide plus propranolol in essential hypertension
    • Semplicini A, Rossi GP, Bongiovi S, et al. Time course of changes in blood pressure, aldosterone and body fluids during enalapril treatment: a double-blind randomized study vs hydrochlorothiazide plus propranolol in essential hypertension. Clin Exp Pharmacol Physiol. 1986;13:17-24.
    • (1986) Clin Exp Pharmacol Physiol , vol.13 , pp. 17-24
    • Semplicini, A.1    Rossi, G.P.2    Bongiovi, S.3
  • 9
    • 0014900991 scopus 로고
    • Central inhibition of reflex vasodilatation by angiotensin and reduced renal pressure
    • Sweet CS, Brody MJ. Central inhibition of reflex vasodilatation by angiotensin and reduced renal pressure. Am J Physiol. 1970;219:1751-1758.
    • (1970) Am J Physiol , vol.219 , pp. 1751-1758
    • Sweet, C.S.1    Brody, M.J.2
  • 10
    • 0019065676 scopus 로고
    • Central site for pressor action of blood-borne angiotensin in rat
    • Fink GD, Haywood JR, Bryan WJ, et al. Central site for pressor action of blood-borne angiotensin in rat. Am J Physiol. 1980;239:R358-R361.
    • (1980) Am J Physiol , vol.239
    • Fink, G.D.1    Haywood, J.R.2    Bryan, W.J.3
  • 11
    • 0035074165 scopus 로고    scopus 로고
    • Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research
    • Bader M, Peters J, Baltatu O, et al. Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research. J Mol Med. 2001;79:76-102.
    • (2001) J Mol Med , vol.79 , pp. 76-102
    • Bader, M.1    Peters, J.2    Baltatu, O.3
  • 12
    • 0035214442 scopus 로고    scopus 로고
    • The clinical implication of tissue renin angiotensin systems
    • Re RN. The clinical implication of tissue renin angiotensin systems. Curr Opin Cardiol. 2001;16:317-327.
    • (2001) Curr Opin Cardiol , vol.16 , pp. 317-327
    • Re, R.N.1
  • 13
    • 30944453306 scopus 로고    scopus 로고
    • Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors
    • Ferrario CM, Jessup J, Gallagher PE, et al. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int. 2005;68:2189-2196.
    • (2005) Kidney Int , vol.68 , pp. 2189-2196
    • Ferrario, C.M.1    Jessup, J.2    Gallagher, P.E.3
  • 14
    • 42649114447 scopus 로고    scopus 로고
    • Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats
    • Hamming I, van Goor H, Turner AJ, et al. Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats. Exp Physiol. 2008;93:631-638.
    • (2008) Exp Physiol , vol.93 , pp. 631-638
    • Hamming, I.1    van Goor, H.2    Turner, A.J.3
  • 15
    • 0027222840 scopus 로고
    • Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart
    • Urata H, Boehm KD, Philip A, et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest. 1993;91:1269-1281.
    • (1993) J Clin Invest , vol.91 , pp. 1269-1281
    • Urata, H.1    Boehm, K.D.2    Philip, A.3
  • 16
    • 0031762019 scopus 로고    scopus 로고
    • Functional role of chymase in angiotensin II formation in human vascular tissue
    • Takai S, Shiota N, Jin D, et al. Functional role of chymase in angiotensin II formation in human vascular tissue. J Cardiovasc Pharmacol. 1998;32:826-833.
    • (1998) J Cardiovasc Pharmacol , vol.32 , pp. 826-833
    • Takai, S.1    Shiota, N.2    Jin, D.3
  • 17
    • 0028948159 scopus 로고
    • Progressive improvement in the structure of resistance arteries of hypertensive patients after 2years of treatment with an angiotensin I-converting enzyme inhibitor. Comparison with effects of a beta-blocker
    • Schiffrin EL, Deng LY, Larochelle P. Progressive improvement in the structure of resistance arteries of hypertensive patients after 2years of treatment with an angiotensin I-converting enzyme inhibitor. Comparison with effects of a beta-blocker. Am J Hypertens. 1995;8:229-236.
    • (1995) Am J Hypertens , vol.8 , pp. 229-236
    • Schiffrin, E.L.1    Deng, L.Y.2    Larochelle, P.3
  • 18
    • 0038642326 scopus 로고    scopus 로고
    • A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension
    • Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41-46.
    • (2003) Am J Med , vol.115 , pp. 41-46
    • Klingbeil, A.U.1    Schneider, M.2    Martus, P.3
  • 19
    • 0031601718 scopus 로고    scopus 로고
    • Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis
    • Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension. 1998;31:181-188.
    • (1998) Hypertension , vol.31 , pp. 181-188
    • Border, W.A.1    Noble, N.A.2
  • 20
    • 0017363902 scopus 로고
    • Mild high-renin essential hypertension: neurogenic human hypertension?
    • Esler M, Julius S, Zweifler A, et al. Mild high-renin essential hypertension: neurogenic human hypertension? N Engl J Med. 1977;296:405-411.
    • (1977) N Engl J Med , vol.296 , pp. 405-411
    • Esler, M.1    Julius, S.2    Zweifler, A.3
  • 21
    • 0026074402 scopus 로고
    • Hyperkinetic borderline hypertension in Tecumseh, Michigan
    • Julius S, Krause L, Schork NJ, et al. Hyperkinetic borderline hypertension in Tecumseh, Michigan. J Hypertens. 1991;9:77-84.
    • (1991) J Hypertens , vol.9 , pp. 77-84
    • Julius, S.1    Krause, L.2    Schork, N.J.3
  • 22
    • 0019925250 scopus 로고
    • Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure
    • Levine TB, Francis GS, Goldsmith SR, et al. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol. 1982;49:1659-1666.
    • (1982) Am J Cardiol , vol.49 , pp. 1659-1666
    • Levine, T.B.1    Francis, G.S.2    Goldsmith, S.R.3
  • 23
    • 0031896734 scopus 로고    scopus 로고
    • Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives
    • Weir MR, Chrysant SG, McCarron DA, et al. Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. Hypertension. 1998;31:1088-1096.
    • (1998) Hypertension , vol.31 , pp. 1088-1096
    • Weir, M.R.1    Chrysant, S.G.2    McCarron, D.A.3
  • 24
    • 0030068699 scopus 로고    scopus 로고
    • Salt sensitivity of hypertension and responses to angiotensin converting enzyme inhibition with benazepril
    • Moore TJ, Rich G, McKnight JA, et al. Salt sensitivity of hypertension and responses to angiotensin converting enzyme inhibition with benazepril. Am J Hypertens. 1996;9:54-60.
    • (1996) Am J Hypertens , vol.9 , pp. 54-60
    • Moore, T.J.1    Rich, G.2    McKnight, J.A.3
  • 25
    • 0024512092 scopus 로고
    • Prolonged converting enzyme inhibition in non-modulating hypertension
    • Dluhy RG, Smith K, Taylor T, et al. Prolonged converting enzyme inhibition in non-modulating hypertension. Hypertension. 1989;13:371-377.
    • (1989) Hypertension , vol.13 , pp. 371-377
    • Dluhy, R.G.1    Smith, K.2    Taylor, T.3
  • 26
    • 0018237275 scopus 로고
    • Age versus urinary sodium for judging renin, aldosterone, and catecholamine levels: studies in normal subjects and patients with essential hypertension
    • Weidmann P, Beretta-Piccoli C, Ziegler WH, et al. Age versus urinary sodium for judging renin, aldosterone, and catecholamine levels: studies in normal subjects and patients with essential hypertension. Kidney Int. 1978;14:619-632.
    • (1978) Kidney Int , vol.14 , pp. 619-632
    • Weidmann, P.1    Beretta-Piccoli, C.2    Ziegler, W.H.3
  • 27
    • 0023516096 scopus 로고
    • Influence of age on blood pressure response to enalapril
    • Cooper WD, Glover DR, Kimber GR. Influence of age on blood pressure response to enalapril. Gerontology. 1987;33(suppl 1):48-54.
    • (1987) Gerontology , vol.33 , Issue.SUPPL. 1 , pp. 48-54
    • Cooper, W.D.1    Glover, D.R.2    Kimber, G.R.3
  • 28
    • 0018446777 scopus 로고
    • Racial differences in pressure, volume and renin interrelationships in essential hypertension
    • Chrysant SG, Danisa K, Kem DC, et al. Racial differences in pressure, volume and renin interrelationships in essential hypertension. Hypertension. 1979;1:136-141.
    • (1979) Hypertension , vol.1 , pp. 136-141
    • Chrysant, S.G.1    Danisa, K.2    Kem, D.C.3
  • 29
    • 58149263565 scopus 로고    scopus 로고
    • Blood pressure guidelines - where are we now?
    • Blood pressure guidelines - where are we now? Drug Ther Bull. 2008;46:65-69.
    • (2008) Drug Ther Bull , vol.46 , pp. 65-69
  • 30
    • 0036324669 scopus 로고    scopus 로고
    • ACE genotype and ACE inhibitor response in kidney disease: a perspective
    • Mayer G. ACE genotype and ACE inhibitor response in kidney disease: a perspective. Am J Kidney Dis. 2002;40:227-235.
    • (2002) Am J Kidney Dis , vol.40 , pp. 227-235
    • Mayer, G.1
  • 31
    • 0033962808 scopus 로고    scopus 로고
    • Chronic proteinuric nephropathies II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (GISEN)
    • Ruggenenti P, Perna A, Zoccali C, et al. Chronic proteinuric nephropathies II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (GISEN). J Am Soc Nephrol. 2000;11:88-96.
    • (2000) J Am Soc Nephrol , vol.11 , pp. 88-96
    • Ruggenenti, P.1    Perna, A.2    Zoccali, C.3
  • 32
    • 0030585729 scopus 로고    scopus 로고
    • Deletion polymorphism of the angiotensin-converting enzyme gene is independently associated with left ventricular mass and geometric remodeling in systemic hypertension
    • Gharavi AG, Lipkowitz MS, Diamond JA, et al. Deletion polymorphism of the angiotensin-converting enzyme gene is independently associated with left ventricular mass and geometric remodeling in systemic hypertension. Am J Cardiol. 1996;77:1315-1319.
    • (1996) Am J Cardiol , vol.77 , pp. 1315-1319
    • Gharavi, A.G.1    Lipkowitz, M.S.2    Diamond, J.A.3
  • 33
    • 53749103611 scopus 로고    scopus 로고
    • Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies
    • Ruggenenti P, Bettinaglio P, Pinares F, et al. Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. Clin J Am Soc Nephrol: CJASN. 2008;3:1511-1525.
    • (2008) Clin J Am Soc Nephrol: CJASN , vol.3 , pp. 1511-1525
    • Ruggenenti, P.1    Bettinaglio, P.2    Pinares, F.3
  • 34
    • 0344373794 scopus 로고    scopus 로고
    • Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
    • ALLHAT Officers Coordinators for the ALLHAT Collaborative Research Group
    • ALLHAT Officers Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288:2981-2997.
    • (2002) JAMA , vol.288 , pp. 2981-2997
  • 35
    • 0345492460 scopus 로고    scopus 로고
    • A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial
    • Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805-2816.
    • (2003) JAMA , vol.290 , pp. 2805-2816
    • Pepine, C.J.1    Handberg, E.M.2    Cooper-DeHoff, R.M.3
  • 36
    • 24644443331 scopus 로고    scopus 로고
    • Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
    • Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906.
    • (2005) Lancet , vol.366 , pp. 895-906
    • Dahlof, B.1    Sever, P.S.2    Poulter, N.R.3
  • 37
    • 0034688194 scopus 로고    scopus 로고
    • Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study
    • Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study. N Engl J Med. 2000;342:145-153.
    • (2000) N Engl J Med , vol.342 , pp. 145-153
    • Yusuf, S.1    Sleight, P.2    Pogue, J.3
  • 38
    • 17044440752 scopus 로고    scopus 로고
    • Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy
    • Svensson P, de Faire U, Sleight P, et al. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension. 2001;38:E28-E32.
    • (2001) Hypertension , vol.38
    • Svensson, P.1    de Faire, U.2    Sleight, P.3
  • 39
    • 0026786643 scopus 로고
    • Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators
    • Pfeffer MA, Braunwald E, Moyé LA. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669-677.
    • (1992) N Engl J Med , vol.327 , pp. 669-677
    • Pfeffer, M.A.1    Braunwald, E.2    Moyé, L.A.3
  • 40
    • 0027423378 scopus 로고
    • Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators
    • Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342:821-828.
    • (1993) Lancet , vol.342 , pp. 821-828
  • 41
    • 9044239676 scopus 로고
    • A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction
    • Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:1670-1676.
    • (1995) N Engl J Med , vol.333 , pp. 1670-1676
    • Kober, L.1    Torp-Pedersen, C.2    Carlsen, J.E.3
  • 42
    • 0028816282 scopus 로고
    • The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction
    • Ambrosioni E, Borghi C, Magnani B, et al. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med. 1995;332:80-85.
    • (1995) N Engl J Med , vol.332 , pp. 80-85
    • Ambrosioni, E.1    Borghi, C.2    Magnani, B.3
  • 43
    • 0010838455 scopus 로고    scopus 로고
    • Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients
    • Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000;355:1575-1581.
    • (2000) Lancet , vol.355 , pp. 1575-1581
    • Flather, M.D.1    Yusuf, S.2    Køber, L.3
  • 44
    • 0028273258 scopus 로고
    • Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction
    • Gruppo GISSI 3
    • Gruppo GISSI 3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994;343:1115-1122.
    • (1994) Lancet , vol.343 , pp. 1115-1122
  • 45
    • 0028932732 scopus 로고
    • A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Fourth International Study of Infarct Survival (ISIS-4)
    • Fourth International Study of Infarct Survival (ISIS-4)
    • Fourth International Study of Infarct Survival (ISIS-4). A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58, 050 patients with suspected acute myocardial infarction. Fourth International Study of Infarct Survival (ISIS-4). Lancet. 1995;345:669-685.
    • (1995) Lancet , vol.345 , pp. 669-685
  • 46
    • 0028961295 scopus 로고
    • Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CC-1)
    • Chinese Collaborative Study Coordinating Group
    • Chinese Collaborative Study Coordinating Group. Oral captopril versus placebo among 13, 634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CC-1). Lancet. 1995;345:686-687.
    • (1995) Lancet , vol.345 , pp. 686-687
  • 47
    • 10944239058 scopus 로고    scopus 로고
    • ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction)
    • Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. 2004;110:e82-e292.
    • (2004) Circulation , vol.110
    • Antman, E.M.1    Anbe, D.T.2    Armstrong, P.W.3
  • 48
    • 0035810547 scopus 로고    scopus 로고
    • Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial
    • Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385-1390.
    • (2001) Lancet , vol.357 , pp. 1385-1390
    • Dargie, H.J.1
  • 49
    • 0034612118 scopus 로고    scopus 로고
    • Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II
    • Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-1587.
    • (2000) Lancet , vol.355 , pp. 1582-1587
    • Pitt, B.1    Poole-Wilson, P.A.2    Segal, R.3
  • 50
    • 0037036971 scopus 로고    scopus 로고
    • Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan
    • Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360:752-760.
    • (2002) Lancet , vol.360 , pp. 752-760
    • Dickstein, K.1    Kjekshus, J.2
  • 51
    • 0242490542 scopus 로고    scopus 로고
    • Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
    • Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906.
    • (2003) N Engl J Med , vol.349 , pp. 1893-1906
    • Pfeffer, M.A.1    McMurray, J.J.2    Velazquez, E.J.3
  • 52
    • 0023266532 scopus 로고
    • Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
    • CONSENSUS Trial Group
    • CONSENSUS Trial Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
    • (1987) N Engl J Med , vol.316 , pp. 1429-1435
  • 53
    • 0025913812 scopus 로고
    • Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
    • SOLVD Investigators
    • SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
    • (1991) N Engl J Med , vol.325 , pp. 293-302
  • 54
    • 0026785561 scopus 로고
    • Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
    • SOLVD Investigators
    • SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-91.
    • (1992) N Engl J Med , vol.327 , pp. 685-691
  • 55
    • 0037716744 scopus 로고    scopus 로고
    • Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study
    • Jong P, Yusuf S, Rousseau MF, et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet. 2003;361:1843-1848.
    • (2003) Lancet , vol.361 , pp. 1843-1848
    • Jong, P.1    Yusuf, S.2    Rousseau, M.F.3
  • 56
    • 0025770138 scopus 로고
    • A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
    • Cohn JN, Johnson GA, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-310.
    • (1991) N Engl J Med , vol.325 , pp. 303-310
    • Cohn, J.N.1    Johnson, G.A.2    Ziesche, S.3
  • 57
    • 33748988737 scopus 로고    scopus 로고
    • The perindopril in elderly people with chronic heart failure (PEP-CHF) study
    • Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338-2345.
    • (2006) Eur Heart J , vol.27 , pp. 2338-2345
    • Cleland, J.G.1    Tendera, M.2    Adamus, J.3
  • 58
    • 0022503155 scopus 로고
    • Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension
    • Zatz R, Dunn BR, Meyer TW, et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest. 1986;77:1925-1930.
    • (1986) J Clin Invest , vol.77 , pp. 1925-1930
    • Zatz, R.1    Dunn, B.R.2    Meyer, T.W.3
  • 59
    • 0027517659 scopus 로고
    • The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
    • Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
    • (1993) N Engl J Med , vol.329 , pp. 1456-1462
    • Lewis, E.J.1    Hunsicker, L.G.2    Bain, R.P.3
  • 60
    • 0141789624 scopus 로고    scopus 로고
    • Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis
    • Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Int Medicine. 2003;139:244-252.
    • (2003) Ann Int Medicine , vol.139 , pp. 244-252
    • Jafar, T.H.1    Stark, P.C.2    Schmid, C.H.3
  • 61
    • 67649635807 scopus 로고    scopus 로고
    • Renal and retinal effects of enalapril and losartan in type 1 diabetes
    • Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361:40-51.
    • (2009) N Engl J Med , vol.361 , pp. 40-51
    • Mauer, M.1    Zinman, B.2    Gardiner, R.3
  • 62
    • 0028215329 scopus 로고
    • The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group
    • Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Eng J Med. 1994;330:877-884.
    • (1994) N Eng J Med , vol.330 , pp. 877-884
    • Klahr, S.1    Levey, A.S.2    Beck, G.J.3
  • 63
    • 15844414184 scopus 로고    scopus 로고
    • Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial
    • Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365:939-946.
    • (2005) Lancet , vol.365 , pp. 939-946
    • Ruggenenti, P.1    Perna, A.2    Loriga, G.3
  • 64
    • 0035816018 scopus 로고    scopus 로고
    • Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. [see comment]
    • Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. [see comment]. JAMA. 2001;285:2719-2728.
    • (2001) JAMA , vol.285 , pp. 2719-2728
    • Agodoa, L.Y.1    Appel, L.2    Bakris, G.L.3
  • 65
    • 0037145856 scopus 로고    scopus 로고
    • Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial
    • Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421-2431.
    • (2002) JAMA , vol.288 , pp. 2421-2431
    • Wright Jr., J.T.1    Bakris, G.2    Greene, T.3
  • 66
    • 42949139975 scopus 로고    scopus 로고
    • Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans
    • Appel LJ, Wright JT Jr, Greene T, et al. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Int Med. 2008;168:832-839.
    • (2008) Arch Int Med , vol.168 , pp. 832-839
    • Appel, L.J.1    Wright Jr., J.T.2    Greene, T.3
  • 67
    • 30444452987 scopus 로고    scopus 로고
    • Efficacy and safety of benazepril for advanced chronic renal insufficiency
    • Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006;354:131-140.
    • (2006) N Engl J Med , vol.354 , pp. 131-140
    • Hou, F.F.1    Zhang, X.2    Zhang, G.H.3
  • 68
    • 0035968623 scopus 로고    scopus 로고
    • Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack
    • Progress Collaborative Group
    • Progress Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
    • (2001) Lancet , vol.358 , pp. 1033-1041
  • 69
    • 33646829274 scopus 로고    scopus 로고
    • Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial
    • Arima H, Chalmers J, Woodward M, et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens. 2006;24:1201-1208.
    • (2006) J Hypertens , vol.24 , pp. 1201-1208
    • Arima, H.1    Chalmers, J.2    Woodward, M.3
  • 70
    • 0038669268 scopus 로고    scopus 로고
    • Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease
    • Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Int Med. 2003;163:1069-1075.
    • (2003) Arch Int Med , vol.163 , pp. 1069-1075
    • Tzourio, C.1    Anderson, C.2    Chapman, N.3
  • 71
    • 73849098313 scopus 로고    scopus 로고
    • Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy
    • Bavry AA, Anderson RD, Gong Y, et al. Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy. Hypertension. 2010;55:48-53.
    • (2010) Hypertension , vol.55 , pp. 48-53
    • Bavry, A.A.1    Anderson, R.D.2    Gong, Y.3
  • 72
    • 0017367179 scopus 로고
    • A specific orally active inhibitor of angiotensin-converting enzyme in man
    • Ferguson RK, Turini GA, Brunner HR, et al. A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet. 1977;1:775-778.
    • (1977) Lancet , vol.1 , pp. 775-778
    • Ferguson, R.K.1    Turini, G.A.2    Brunner, H.R.3
  • 73
    • 0025066069 scopus 로고
    • A comparison of lisinopril with enalapril by monitoring plasma angiotensin II levels in humans
    • Kawamura M, Imanishi M, Matsushima Y, et al. A comparison of lisinopril with enalapril by monitoring plasma angiotensin II levels in humans. Jpn J Pharmacol. 1990;54:143-149.
    • (1990) Jpn J Pharmacol , vol.54 , pp. 143-149
    • Kawamura, M.1    Imanishi, M.2    Matsushima, Y.3
  • 74
    • 0032900380 scopus 로고    scopus 로고
    • Physician prescribing patterns of ACE inhibitors in secondary prevention post myocardial infarction
    • Luzier AB, Navsarikar A, Wilson M, et al. Physician prescribing patterns of ACE inhibitors in secondary prevention post myocardial infarction. Pharmacotherapy. 1999;19:655-660.
    • (1999) Pharmacotherapy , vol.19 , pp. 655-660
    • Luzier, A.B.1    Navsarikar, A.2    Wilson, M.3
  • 75
    • 0031843983 scopus 로고    scopus 로고
    • Impact of angiotensin-converting enzyme inhibitors underdosing on rehospitalization rates in congestive heart failure
    • Luzier AB, Forrest A, Adelman M, et al. Impact of angiotensin-converting enzyme inhibitors underdosing on rehospitalization rates in congestive heart failure. Am J Cardiol. 1998;82:465-469.
    • (1998) Am J Cardiol , vol.82 , pp. 465-469
    • Luzier, A.B.1    Forrest, A.2    Adelman, M.3
  • 76
    • 0034284115 scopus 로고    scopus 로고
    • Containment of heart failure hospitalizations and cost by angiotensin-converting enzyme inhibitor dosage optimization
    • Luzier AB, Forrest A, Feuerstein SG, et al. Containment of heart failure hospitalizations and cost by angiotensin-converting enzyme inhibitor dosage optimization. Am J Cardiol. 2000;86:519-523.
    • (2000) Am J Cardiol , vol.86 , pp. 519-523
    • Luzier, A.B.1    Forrest, A.2    Feuerstein, S.G.3
  • 77
    • 0020448825 scopus 로고
    • Antihypertensive therapy with MK 421: angiotensin II - renin relationships to evaluate efficacy of converting enzyme blockade
    • Biollaz J, Brunner HR, Gavras I, et al. Antihypertensive therapy with MK 421: angiotensin II - renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol. 1982;4:966-972.
    • (1982) J Cardiovasc Pharmacol , vol.4 , pp. 966-972
    • Biollaz, J.1    Brunner, H.R.2    Gavras, I.3
  • 78
    • 7944227453 scopus 로고    scopus 로고
    • Antihypertensive efficacy of candesartan-lisinopril in combination vs. up-titration of lisinopril: the AMAZE trials
    • Izzo JL Jr, Weinberg MS, Hainer JW, et al. Antihypertensive efficacy of candesartan-lisinopril in combination vs. up-titration of lisinopril: the AMAZE trials. J Clin Hypertens. 2004;6:485-493.
    • (2004) J Clin Hypertens , vol.6 , pp. 485-493
    • Izzo Jr., J.L.1    Weinberg, M.S.2    Hainer, J.W.3
  • 79
    • 42049107348 scopus 로고    scopus 로고
    • Telmisartan, ramipril, or both in patients at high risk for vascular events
    • Pogue J
    • Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
    • (2008) N Engl J Med , vol.358 , pp. 1547-1559
    • Yusuf, S.1    Teo, K.K.2
  • 80
    • 0018607402 scopus 로고
    • Hormonal changes with long-term converting-enzyme inhibition by captopril in essential hypertension
    • Matthews PG, McGrath BP, Johnston CI. Hormonal changes with long-term converting-enzyme inhibition by captopril in essential hypertension. Clin Sci. 1979;57(suppl 5):135s-138s.
    • (1979) Clin Sci , vol.57 , Issue.SUPPL. 5
    • Matthews, P.G.1    McGrath, B.P.2    Johnston, C.I.3
  • 81
    • 0024410707 scopus 로고
    • Clinical pharmacology of ACE inhibition
    • Nussberger J, Waeber B, Brunner HR. Clinical pharmacology of ACE inhibition. Cardiol. 1989;76(suppl 2):11-22.
    • (1989) Cardiol , vol.76 , Issue.SUPPL. 2 , pp. 11-22
    • Nussberger, J.1    Waeber, B.2    Brunner, H.R.3
  • 82
    • 0030760332 scopus 로고    scopus 로고
    • Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure
    • Grassi G, Cattaneo BM, Seravalle G, et al. Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation. 1997;96:1173-1179.
    • (1997) Circulation , vol.96 , pp. 1173-1179
    • Grassi, G.1    Cattaneo, B.M.2    Seravalle, G.3
  • 83
    • 0036069796 scopus 로고    scopus 로고
    • Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?
    • Ahmed A. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine? J Am Geriatrics Soc. 2002;50:1297-1300.
    • (2002) J Am Geriatrics Soc , vol.50 , pp. 1297-1300
    • Ahmed, A.1
  • 84
    • 0034642827 scopus 로고    scopus 로고
    • Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?
    • Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Int Med. 2000;160:685-693.
    • (2000) Arch Int Med , vol.160 , pp. 685-693
    • Bakris, G.L.1    Weir, M.R.2
  • 85
    • 0036528757 scopus 로고    scopus 로고
    • Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs
    • Deary AJ, Schumann AL, Murfet H, et al. Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens. 2002;20:771-777.
    • (2002) J Hypertens , vol.20 , pp. 771-777
    • Deary, A.J.1    Schumann, A.L.2    Murfet, H.3
  • 86
    • 34548383480 scopus 로고    scopus 로고
    • 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension
    • Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007;25:1751-1762.
    • (2007) J Hypertens , vol.25 , pp. 1751-1762
    • Mancia, G.1    De Backer, G.2    Dominiczak, A.3
  • 87
    • 0038460302 scopus 로고    scopus 로고
    • The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: JNC 7 Express
    • Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: JNC 7 Express. JAMA. 2003;289:2560-2572.
    • (2003) JAMA , vol.289 , pp. 2560-2572
    • Chobanian, A.V.1    Bakris, G.L.2    Black, H.R.3
  • 88
    • 67650070753 scopus 로고    scopus 로고
    • Effect of telmisartan on renal outcomes: a randomized trial
    • Mann JFE, Schmieder RE, Dyal L, et al. Effect of telmisartan on renal outcomes: a randomized trial. Ann Internal Med. 2009;151:1-10.
    • (2009) Ann Internal Med , vol.151 , pp. 1-10
    • Mann, J.F.E.1    Schmieder, R.E.2    Dyal, L.3
  • 89
    • 0041408235 scopus 로고    scopus 로고
    • Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
    • McMurray JJV, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767-771.
    • (2003) Lancet , vol.362 , pp. 767-771
    • McMurray, J.J.V.1    Ostergren, J.2    Swedberg, K.3
  • 90
    • 33646094699 scopus 로고    scopus 로고
    • Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: assessment of reduction in mortality and morbidity (CHARM)-added trial
    • McMurray JJV, Young JB, Dunlap ME, et al. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: assessment of reduction in mortality and morbidity (CHARM)-added trial. Am Heart J. 2006;151:985-991.
    • (2006) Am Heart J , vol.151 , pp. 985-991
    • McMurray, J.J.V.1    Young, J.B.2    Dunlap, M.E.3
  • 91
    • 49749086129 scopus 로고    scopus 로고
    • Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression
    • Catapano F, Chiodini P, De Nicola L, et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis. 2008;52:475-485.
    • (2008) Am J Kidney Dis , vol.52 , pp. 475-485
    • Catapano, F.1    Chiodini, P.2    De Nicola, L.3
  • 92
    • 77952106918 scopus 로고    scopus 로고
    • Combination therapy in hypertension
    • American Society of Hypertension Writing Group
    • Gradman AH, Basile JN, Carter BL, Bakris GL, American Society of Hypertension Writing Group. Combination therapy in hypertension. J Am Soc Hyperten. 2010;4:42-50.
    • (2010) J Am Soc Hyperten , vol.4 , pp. 42-50
    • Gradman, A.H.1    Basile, J.N.2    Carter, B.L.3    Bakris, G.L.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.